PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas
Authors' conclusion
Our findings highlight that the activation of the PI3K/AKT/mTOR pathyway in PCa patients suggests their degree of malignancy, possibly leading to poor outcomes.
Study context
- Population
- Patients with parathyroid carcinoma recruited from dual centers over a 10-year period; follow-up up to 117 months66 tumor tissues sequenced
- Participants
- 64 vs 29
- Comparison
- Parathyroid carcinoma (PCa) vs controls; PI3K/AKT/mTOR-mutated vs no targeted variants
- PCan = 64
- Controlsn = 29reference
- Outcome
- mTORC1 activity (immunohistochemistry)
Methodological detailsdual-centre
- Dual-centre
Main finding
As reported in the abstract
| Outcome | PCa |
|---|---|
| High mTORC1 | 48.5% |
Further findings
- PI3K/AKT/mTOR variants in PCa samples
- 24.2% · 16
- Biochemistry and survival: PI3K/AKT/mTOR-mutated vs no targeted variants · follow-up up to 117 months · significantly lower disease-free survival (DFS) with PI3K/AKT/mTOR-mutated
- P < 0.001
- Biochemistry and survival: PI3K/AKT/mTOR-mutated vs no targeted variants · follow-up up to 117 months · significantly lower overall survival (OS) with PI3K/AKT/mTOR-mutated
- P < 0.01
- PI3K/AKT/mTOR variants in PCa samples: 16/66 samples
PI3K/AKT/mTOR variants in PCa samples
- Majority of variant cases lacked CDC73 variants
- Higher mTORC1 activity in PCa with vs without PI3K/AKT/mTOR variants
Biochemistry and survival: PI3K/AKT/mTOR-mutated vs no targeted variants · follow-up up to 117 months
- Higher serum PTH, alkaline phosphatase and creatinine in PI3K/AKT/mTOR-mutated group
Original publication
PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas. J Clin Endocrinol Metab. Published 20 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →